Over the past 9 days, AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) stock was observed to have a Historic Volatility of 52.93%. That figure, when expanded to look at the past 100 days, ACRX goes up to 60.64%. In the last 5 days, this stock’s average daily volume is shown as 2,136,560 shares per day, which is higher than the average of 2,073,162 shares per day as measured over the last 100 days. Moving on to look at the price, the movement in the past 5 days was -0.42, while this stock’s price moved -17.16% lower in the past 100 days.
A widely-used method of evaluating a stock’s price at any given moment is looking at it in relation to its 52-week price range. This stock’s recent rise arrives on a trading day that exhibited higher volume than its usual average of 2.39M (measured over the past 3 months). On May 15th, 2019, volume rose to about 2,599,561 transactions. During the trading period, the first transaction completed was recorded at $3.09 per share, which has dropped by -1.90% by closing bell when the final transaction of the day was recorded at $3.15. At the moment, this stock’s 52-week high is $5.05 and its 52-week low is $1.99.
This publicly-traded organization managed to generate a trailing 12-month revenue of 2.10M. Bearing that in mind, this company is experiencing top-line progress, as its year-over-year quarterly revenue has grown by -14.30%. This company’s current market capitalization is 234.22M.
Recently, AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) has caught the attention – and in-depth analysis – of numerous Wall Street analysts. In a research note published on April 24th, 2019 from B. Riley FBR Resumed the shares of ACRX to $6.50. Similarly, in a research note sent out on February 15th, 2019 from Credit Suisse, analysts Initiated the shares of this stock to Outperform and set a price target at $7.Additionally, in a research note made public on October 23rd, 2018, Analysts at B. Riley FBR Initiated common shares of ACRX stock to Buy – combined with a 12-month price target of $9.
Is Ironwood Pharmaceuticals, Inc. a good investment? Let’s take a look at what leading Wall Street experts have to say about this particular stock. For shares of Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), there are currently ratings available from 7 different stock market analysts who have all given their professional opinions. On average, these analysts currently have a Hold recommendation with a mean rating of 3.14. This is in comparison to the average recommendation from a month ago, which was a Hold with an average rating of 3.33. Similarly, the average rating observed 2 months ago was a Hold with the mean numerical rating of 3.11, and the average rating observed 3 months ago was a Hold with a mean numerical rating of 2.89.
But what do Wall Street experts have to say about how this company is performing behind the scenes? Looking at its overall profits, Ironwood Pharmaceuticals, Inc. reported earnings of -0.26 for the quarter ending Mar-19. This compares to the average analyst prediction of -0.14, representing a difference of -0.12, and therefore a surprise factor of -91.74. For the financial results of the preceding quarter, the company posted earnings of -0.02, in comparison to the average analyst forecast of -0.15 – representing a difference of 0.13 and a surprise factor of -86.48.
Continuing discussion of current price performance, Ironwood Pharmaceuticals, Inc. has a total market value of 1.55B at the time of writing – representing $157.97M outstanding shares. Turning to other widely-considered trading data, this company’s half yearly performance is observed to be negative at -1.45%. The Average True Range for this company’s stock is currently 0.50, and its current Beta is sitting at 1.85.
Now let’s take a look at what’s on the horizon: for the financial results of the current quarter, So far – there have been 6 different Wall Street analysts that have provided investors with their professional projections for Ironwood Pharmaceuticals, Inc. For net profit, these analysts are collectively forecasting an average estimate of -$0.07 per share, versus the -$0.28 per share reported in the year-ago quarter. The lowest earnings per share prediction was $0.02 per share, with the highest forecast pointing toward $0.14 per share. Compared to the year-ago period, experts are projecting a growth rate of +75.00%.